Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731008 | 0.97 | — | — | |
| SCHEMBL2241191 | 0.95 | — | — | |
| SCHEMBL157427 | 0.92 | CYP2D6 (0.33) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL2778573 | 0.92 | — | — | |
| SCHEMBL2229452 | 0.90 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL286072 | 0.90 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL4712511 | 0.90 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL6050828 | 0.90 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL3658217 | 0.90 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL2569149 | 0.90 | CYP2D6 (0.32) | CYP2D6MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4058390-A | Amine salts of phenyl-4-hydroxypyridazines and the preparation and herbicidal compositions thereof | CHEMIE LINZ AKTIENGESELLSCHAFT (OE) | 1977-11-15 | — | — | US | claimed |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | NEUROPN THERAPEUTICS (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240139172-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NeuroPn Therapeutics, Inc. (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2024073648-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | NeuroPn Therapeutics, Inc. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240075023-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | NeuroPn Therapeutics, Inc. (US) | 2024-03-07 | — | — | US | disclosed |
| EP-4323341-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Neuropn Therapeutics, LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| US-9656955-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9550754-B2 | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-01-24 | — | — | US | disclosed |
| US-9365512-B2 | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-06-14 | — | — | US | disclosed |
| US-20160145197-A1 | PROCESS FOR PREPARING BICYCLIC AMINE DERIVATIVES | ABBVIE INC. | 2016-05-26 | — | — | US | disclosed |
| US-20100184820-A1 | COMBINATIONS COMPRISING STAUROSPORINES | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| EP-1951213-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | Morvus Technology Ltd. (GB) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007074344-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | MORVUS TECHNOLOGY LIMITED (GB) | 2007-07-05 | — | — | WO | disclosed |
| EP-1363900-B1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | CELGENE CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20070015662-A1 | Herbicide/safener combination | BAYER CROPSCIENCE GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
| US-6013836-A | PARTICULARLY ACTIVE AGAINST MOTHS AND BEETLES AND THEIR INSECT GROWTH REGULATING ACTIVITY WITHOUT ADVERSE IMPACT ON BENEFICIAL INSECTS; CROPS; FORESTRY | ROHM AND HAAS COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| WO-1995015955-A1 | 2,4-DIAMINOTHIAZOLES AND THEIR PRODUCTION | BASF AKTIENGESELLSCHAFT (DE) | 1995-06-15 | — | — | WO | disclosed |
| US-4767769-A | HISTAMINE-H2 ANTAGONISTS | THE BOOTS COMPANY PLC (GB) | 1988-08-30 | — | — | US | disclosed |
| US-4168311-A | APHIDICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-09-18 | — | — | US | disclosed |
| US-4066637-A | BASIC DIAMINOPYRIDINE-(3)-AZO DYESTUFFS | CIBA-GEIGY CORPORATION (US) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015662-A1 | Herbicide/safener combination | CYP2W1, CBR3, DDT | CYP2D6 56/4885MEN1 3038/4885KMT2A 1526/4885 |
| US-20240139172-A1 | PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY | PDCD1, TP53, CHEK2 | CYP2D6 4456/4885MEN1 4395/4885KMT2A 925/4885 |
| US-20240075023-A1 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, HPGDS | CYP2D6 1859/4885MEN1 4837/4885KMT2A 2930/4885 |
| US-20160145197-A1 | PROCESS FOR PREPARING BICYCLIC AMINE DERIVATIVES | HRH4, HRH3, HRH1 | CYP2D6 1206/4885MEN1 188/4885KMT2A 410/4885 |
| US-20100184820-A1 | COMBINATIONS COMPRISING STAUROSPORINES | MCL1, FLT3, BCL3 | CYP2D6 4810/4885MEN1 2244/4885KMT2A 137/4885 |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, HPGDS | CYP2D6 1859/4885MEN1 4837/4885KMT2A 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.